Rapid Infusion Devices and Cell Salvage in Trauma Resuscitation

Introduction

• Hemorrhage is the leading cause of preventable early trauma death, accounting for over 80% of intraoperative trauma deaths and nearly half of deaths within the first 24 hours.^1,6 Early activation of MTPs improves survival, whereas delayed activation is associated with poorer outcomes.^1,3 Rapid, warmed, high-flow fluid resuscitation mitigates progression to the lethal triad of hypothermia, acidosis, and coagulopathy.^1-3
• Severe hemorrhage often requires infusion rates exceeding 300 mL/min, with flows up to 500 mL/min sometimes necessary during damage-control resuscitation (DCR).² Traditional infusion methods (gravity, pressure bags) cannot meet these requirements. Modern RIDs integrate pressure augmentation, active warming, and air-elimination systems to deliver large-volume warmed blood products safely and efficiently.^1-3 Cell salvage devices provide washed autologous RBCs as an adjunct strategy to reduce allogeneic exposure.⁴

Principles and Technical Foundations

• Refrigerated or room temperature blood products should be warmed to body temperature during resuscitation to avoid iatrogenic hypothermia and coagulopathy.^3,6,7 Hypothermia is independently associated with increased transfusion requirements, morbidity, and mortality.³
• The physiological demands of hemorrhagic shock require infusion systems capable of simultaneously delivering high flow and effective warming. Failure to achieve either compromises the efficacy of resuscitation.^1-3

Principles of RIDs^1,2,5,8

RIDs can deliver large volumes of blood products rapidly and at physiologic temperature. Their performance relies on the integration of several key technologies:

• Pressure augmentation to overcome catheter and tubing resistance, enabling flow rates of 500–1200 mL/min, depending on access and device design.
• Active warming systems, typically countercurrent or dry-heat exchangers, maintain near-normothermia at clinically relevant flow rates.
• Automated air-detection and purge mechanisms that identify and eliminate entrained air before it enters the patient.
• Closed-loop temperature regulation to prevent overheating or temperature drift during high-flow infusion.
• Microaggregate filtration without significant impedance of flow.
• Single-use, non-occlusive circuits that do not require heparinization and minimize mechanical shear.
• Circuits primed with blood products must be discarded after completion of transfusion or within manufacturer-specified time limits. Crystalloid-primed circuits have longer permissible use times based on sterility considerations.

Principles of Warming Devices^1,8

Inline warming devices such as Hotline® and 3M Ranger™ function solely to maintain fluid temperature and do not incorporate pressure augmentation.

• The Hotline uses countercurrent heat exchange, with a heated water bath surrounding a sterile fluid pathway.
• The 3M Ranger employs a dry-heat plate-warming system with a disposable low-mass cassette.
• Both systems provide reliable thermal control at conventional infusion rates, but because they rely on gravity, pressure bags, or external pumps, their maximum flow is substantially lower than that achievable with RIDs. Consequently, they are appropriate for routine or moderate fluid warming but cannot serve as the primary devices for massive transfusion.

Device Performance and Determinants of Flow

Fluid mechanics follows well-established physical principles. However, the clinical performance of RIDs during massive transfusion is determined by the interaction between device capability, vascular access, and circuit tubing configuration.^1,2

Vascular Access: The Dominant Determinant of Performance

Across infusion systems, vascular access caliber is the single most important determinant of achievable flow. See the OA summary on venous access and Poiseuille’s Law (Link).

Large-bore access permits substantially higher flow than smaller peripheral catheters, regardless of device pumping capacity.

• A 9-Fr introducer provides more than sevenfold the conductance of an 18-gauge intravenous (IV) catheter.²
• IV catheters of 7-Fr caliber or higher reach maximum pressurized flow rates of 1000 mL/min.^1,2

Intraosseous (IO) access provides a dependable alternative when IV access is not immediately achievable, but achievable flow rates are typically lower than those obtained through large-bore IV catheters.^1,2

• IO access is best considered a temporizing measure rather than equivalent to large-bore IV access for sustained high-flow transfusion.
• Flow rates are maximized through humeral and sternal IO access as opposed to lower limb IO placement.

Circuit Configuration and System Resistance

RID performance is highly sensitive to circuit resistance.²

• Additional components, such as extension tubing, connectors, 3-way taps, or inline filters, significantly reduce the maximum achievable flow rate.
• Long tubing increases resistance and degrades both flow and warming efficiency.
• Direct connection of the circuit to the catheter hub consistently improves performance.²

Even high-capacity devices demonstrate marked reductions in effective flow when circuit resistance is increased.

Device Pressure Capability and Practical Flow Limits

RIDs generate sufficient pressure to overcome resistance introduced by catheters and tubing; however, increasing device pressure alone cannot fully offset the limitations imposed by small-diameter or long conduits.^1,2,8

• High-pressure capability enables rapid delivery only when paired with low-resistance access and simplified circuits.
• Flow gains diminish when resistance exceeds the device’s capacity to compensate.

Modern RIDs are engineered to meet the demands of DCR, with maximum flow rates ranging from 500 to 1200 mL/min depending on catheter size, device design, and operating pressure.^1,2,8

Warming Performance at High Flow Rates

The warming efficiency of RIDs varies with flow rate and decreases at extreme flows. At flows ≥500 mL/min, warming capability may decline significantly.^1-3,8

• Most modern RIDs maintain near-physiological temperatures at infusion rates commonly used during trauma resuscitation.
• At flow rates > 500ml/min, warming efficiency may decline as the volume of cold fluid entering the system exceeds heating capacity.⁸
• Increasing circuit resistance further degrades thermal performance by prolonging transit time and increasing heat dissipation.⁸

Comparative Device Performance^1,8

Performance differs substantially between RIDs and warming-only systems.

• RIDs integrate high flow pumping and active warming.
• Warming-only systems provide reliable thermal conditioning but operate at lower flow rates.

Among in-hospital rapid infusers, the Belmont FMS platform reliably combines high flow, consistent warming at 500 mL/min, superior air-elimination performance, and has a reservoir that facilitates large-volume transfusion compared with pressure-based systems.

The Level 1 system achieves high peak flows but shows a greater decline in warming efficiency at higher infusion rates.

The Belmont RI-2 (Figure 1), a newer model in the Belmont platform, has demonstrated effective platelet warming, though comparative data for packed red blood cells (PRBC) or whole blood are not available.⁹

There are portable prehospital devices available, but they are beyond the scope of this review.

Tables 1 and 2 summarize key performance characteristics of hospital rapid infusers and warming-only devices.

Fluid Compatibility

Food and Drug Administration (FDA)-Approved Fluids for RIDs

• PRBCs
• Fresh frozen plasma and thawed plasma
• Crystalloids (normal saline, lactated Ringer’s, balanced salt solutions)
• 5% albumin (compatible; use caution with 25% albumin due to viscosity)

Fluids Used Off-Label with Emerging Safety Data

• Platelets and cryoprecipitate are not FDA-approved for administration via RIDs that incorporate filters, roller pumps, or heat exchangers; however, experimental and laboratory studies have demonstrated that rapid infusers do not significantly impair platelet function or overall hemostatic potential.^7-9
• Given the requirement to rapidly transfuse balanced hemostatic blood resuscitation in trauma MTPs, many institutions recommend and allow the delivery of cryoprecipitate and platelets through RIDs.

Fluids to Avoid^1,7

Circuit Management and Safety

Safe operation of RIDs and effective resuscitation depend on meticulous circuit setup, appropriate vascular access, and continuous clinical monitoring. Although modern RIDs incorporate multiple automated safeguards, adverse events are most commonly attributable to human factors rather than device malfunction. Effective use, therefore, requires disciplined workflow and sustained vigilance throughout resuscitation.

Circuit Setup and Technical Operation⁵

Ensure complete circuit preparation prior to use:

• Fully assembled and ready for immediate use
• Completely primed and purged of all air.
• Free of kinks, obstructions, or unsecured connections

Confirm appropriate vascular access:

• Use access capable of high-flow, high-pressure infusions.
• Verify secure catheter placement and patency prior to initiating rapid infusion.

Verify correct line configuration:

• Connect RID circuits directly to the vascular access hub whenever possible.
• Avoid unnecessary extension tubing, connectors, filters, or stopcocks that increase resistance.
• Reassess circuit integrity during resuscitation and when changing products or infusion parameters.

Utilize and verify device safety features:

• Ensure all air-in-line detection, occlusion alarms, pressure monitoring, and temperature regulation systems are active.
• Recognize that device safeguards supplement, but do not replace clinician vigilance.

Safety and Monitoring

Human factors are the predominant cause of adverse events, not mechanical failure.⁵

Common safety-related errors include:

• Programming or rate selection errors
• Faulty or incomplete priming
• Alarm overrides or bypassing safety features.
• Failure to detect infiltration at high-pressure access sites.
• Inadequate or delayed hemodynamic reassessment.

Clinical monitoring requirements during active infusion:

• Inspect insertion sites frequently for infiltration or extravasation.
• Maintain continuous visual monitoring in pediatric patients.
• Closely observe access sites during pressurized infusion or intraosseous delivery

Hemodynamic and metabolic monitoring:

• Continually reassess blood pressure, heart rate, and perfusion in response to transfusion
• Monitor for rapid volume delivery and risk of volume overload.
• Monitor ionized calcium and potassium levels regularly during massive transfusion and treat as indicated.

Alarm management and team communication:

• Never disable or override safety alarms
• Respond immediately to alarms and investigate the underlying cause.
• Maintain clear communication among team members during high acuity resuscitation.

MTP Integration³

MTP activation and product ratios are fundamental to trauma resuscitation. Current American Association for the Surgery of Trauma/American College of Surgeons Committee on trauma guidelines recommend:³

• Early activation of MTP when hemorrhagic shock is suspected or confirmed^3,10
• Balanced transfusion: 1:1:1 packed red cells: plasma: platelets or utilization of low-titer O whole blood.^3,6
• Permissive hypotension with systolic BP ~80-90 mmHg in patients without traumatic brain injury until hemorrhage control achieved.^3,6
• Minimize crystalloid administration in preference of blood resuscitation.^3,10
• Early tranexamic acid administration within 3 hours of injury in patients with or at risk of significant hemorrhage.³
• Calcium supplementation: (e.g., 1g calcium chloride after first 4 units of blood products) with frequent ionized calcium monitoring.¹⁰
• Active rewarming to maintain core temperature ≥36°C; use inline warming for all blood products during massive transfusion.³
• Minimize time to definitive hemorrhage control^3,10

Cell Salvage

• Cell salvage (Figure 2) is a complementary blood conservation strategy that integrates well with RIDs by providing washed autologous RBCs that can be rapidly reinfused via a RID for warmed delivery. It provides high-quality RBCs without storage lesions or immunologic risks but lacks platelets and coagulation factors, necessitating monitoring during large volume autotransfusion.

Mechanism

1. Collection: Suctioned blood is collected from the operative field using a specialized large-bore suction catheter designed to prevent RBC damage, typically at a lower suction pressure (~150 mmHg). A second catheter, connected to regular suction, is used to aspirate any contaminants (e.g., amniotic fluids, pus, bowel contents) to prevent contamination of salvaged blood.
2. Anticoagulation: Heparin or citrate is added to the reservoir to prevent blood from clotting
3. Processing: RBCs are separated from plasma, contaminants, and debris via centrifugation and/or filtration with washing to provide a product with Hct 50-80%
4. Reinfusion: Washed, concentrated autologous RBCs are transfused via RID or warming device⁴

Cell Salvage Indications and Contraindications

Cost Effectiveness¹¹

• Allogeneic transfusion entails both acquisition costs and substantially higher activity-based costs, including laboratory processing, storage, crossmatching, administration, monitoring, and transfusion-related complications. The total delivered cost of an allogeneic RBC unit is commonly two to four times the acquisition cost, resulting in fully burdened costs in the $300–$800+ range depending on institutional accounting methods.
• Cell salvage becomes cost-advantageous when anticipated blood loss would otherwise necessitate multiple units of allogeneic RBCs. Although capital equipment and ongoing operating expenses are required, the per-unit cost of salvaged RBCs is generally lower than that of allogeneic transfusion in high-volume surgical settings, thereby reducing both allogeneic exposure and total transfusion-related expenditures.

Advantages

• Higher quality RBCs. Salvaged blood has not been subjected to storage effects that occur with banked allogeneic blood.
• Reduces allogeneic transfusion. Cell salvage decreases the need for donor blood transfusion.
• Avoids immunological risks. Autologous blood does not cause immune-related transfusion complications.
• Reduces infection risk. Lower infection rates compared to allogeneic transfusion.
• Reduces hospital length of stay. Associated with shorter hospitalization.
• Cost-effective in high blood loss. When used selectively in surgeries with anticipated large blood loss, it can be more cost-effective than allogeneic blood.

Disadvantages

• Lacks platelets and clotting factors. The washing process removes coagulation factors, requiring monitoring and supplementation during large volume use.
• Potential for RBC injury/Hemolysis risk. Collection and processing can damage RBCs.
• Citrate/heparin spillover. Residual anticoagulant in salvaged blood can cause metabolic effects.
• Risk of reinfusion hypotension. Rapid transfusion of salvaged blood may cause hemodynamic instability.
• Complications with improper use. Requires proper technique and monitoring to avoid complications such as air embolus and coagulopathy.
• Upfront equipment and disposable costs. Requires capital equipment investment and ongoing disposable expense.

Special Populations⁴

1. Obstetric

• Obstetric hemorrhage (postpartum hemorrhage, placenta accreta spectrum disorder, uterine rupture) mirrors trauma physiology in severity and urgency. RIDs (Belmont, Level 1) are widely used in high-risk obstetric cases.
• Cell salvage with a leukocyte depletion filter (LDF) is safe in obstetrics. LDFs remove fetal squamous cells and reduce the theoretical risk of amniotic fluid embolism (AFE). No definite cases of AFE have been reported with modern cell salvage equipment.
• Cell salvage may reduce the need for allogeneic blood transfusion and blood loss while increasing day-one postpartum hemoglobin in pregnant women undergoing caesarean birth.

2. Pediatric

• Children, especially those weighing <20 kg, are at risk of over-transfusion and volume overload, extravasation, and thermal instability. Warmed syringe pumps are therefore often preferred for small volumes.
• RIDs may be used in larger children with low-flow initiation (starting at 50–100 mL/min based on patient size) and continuous visual monitoring for infiltration. Pediatric fluid boluses are typically 10–20 mL/kg, with frequent reassessment between boluses to detect fluid overload.

3. Orthopedic⁴

• Orthopedic surgeries with cementing:
• Cell salvage is safe during cementing arthroplasty and has not been shown to increase the risk of bone cement implantation syndrome. Safety is attributed to effective washing and filtration.

4. Jehovah’s Witness⁴

• Jehovah’s Witnesses hold varying views on cell salvage, with acceptance primarily contingent on a “continuous, closed-circuit” connection to the patient’s circulation. It is important to obtain informed consent.